Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01159028 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
A Phase 1 study, sponsored by Bio-Path Holdings.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01159028 is a Phase 1 study that has completed, run by Bio-Path Holdings. The registered enrollment target is 60 participants.
The verdict
NCT01159028, a Phase 1 study, has completed, sponsored by Bio-Path Holdings.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The first goal of this clinical research study is to find the highest safe dose of BP1001, a liposomal Growth Factor Receptor Bound Protein-2 antisense oligodeoxynucleotide (L-Grb2 AS), for patients with Philadelphia Chromosome positive CML, AML, ALL and MDS. The response of the leukemia to this treatment will also be studied. The second goal of this clinical research study is to evaluate the safety and toxicity of the combination of BP1001 and concurrent low-dose ara-C (LDAC) in patients with AML.
Interventions
- DRUG BP1001
- DRUG BP1001 in combination with LDAC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-06 |
| Est. Completion | 2017-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01159028
The ClinicalTrials.gov registry entry for NCT01159028 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bio-Path Holdings, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BP1001 is the first listed.
NCT01159028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01159028 about?
NCT01159028 is a clinical study titled "Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS". The first goal of this clinical research study is to find the highest safe dose of BP1001, a liposomal Growth Factor Receptor Bound Protein-2 antisense oligodeoxynucleotide (L-Grb2 AS), for patients with Philadelphia Chromosome positive CML, AML, ALL and MDS. The response of the leukemia to this tre...
What is the current status of trial NCT01159028?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2010-06. Estimated completion is 2017-03-30.
What interventions are being tested in trial NCT01159028?
The interventions under investigation include: BP1001 (DRUG), BP1001 in combination with LDAC (DRUG).
Who is sponsoring clinical trial NCT01159028?
This trial is sponsored by Bio-Path Holdings, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.